Equity
€33,507 =
Cabimed 74 paid out €57,246 in dividends. That is 100% of the 2025 profit.
Cabimed 74
Lifetime
9 annual accounts with figures on one time axispeak €122,102 (2024)
€107,372▼ 12.1%
lowest -€13,689 (2019)
€57,246▼ 15.3%
peak €33,507 (2021)
€33,507unchanged
€181,140▲ 5.1%
Board2 names since 2017
2 directors and 1 other
Documentsfilings and deeds
26-06-202635 days before the deadline
2025micro format
Gross margin from €122,102 to €107,372Dividend €57,246Cash from €23,776 to €45,197
Key points
from the 2025 annual accountsChecked score
Bankruptcy probability within 12 months
Financial strength
Score breakdown
Comparable companies, two years later
In July 2024, 6,715 companies had the same profile as Cabimed 74 has now. Each dot stands for 17 companies, two years later.
95.8%
were still trading
2.2%
stopped another way
1.8%
went bankrupt
Another 0.1% stopped without a precise date, possibly only after those two years.
Test of the method
The method was tested on the 497,762 companies of July 2024. Each company was given the bankruptcy share of the same profile a year earlier, in July 2023. The expectation was that 1.6% would go bankrupt within 24 months. In fact 1.7% went bankrupt.
| Group | Expected | Actual |
|---|---|---|
| 1 | 0.2% | 0.2% |
| 2 | 0.3% | 0.5% |
| 3 | 0.5% | 0.6% |
| 4 | 0.7% | 0.8% |
| 5 | 0.9% | 0.9% |
| 6 | 1.3% | 1.5% |
| 7 | 1.6% | 1.8% |
| 8 | 1.8% | 1.8% |
| 9 | 2.9% | 3.1% |
| 10 | 5.6% | 6.1% |
A company that went bankrupt had a higher expected share than one that kept going in 74.5% of comparisons. The level depends on the economy. In a year with more bankruptcies than the year before, the actual share is higher than the expected one.
This is an observation about 6,715 companies, not a prediction for Cabimed 74. The sector does not count, because the KBO no longer lists a sector for a company that has stopped. By sector, mostly the survivors would count, which would paint too rosy a picture.
Credit verdict
Credit check for an amount and term of your choice
Show the recommended maximum and see how the verdict changes with amount, term and advance.
The scores and ratios are Checked's own calculations, not a credit decision.
Signals
Board and ownership
Manager, since 26-06-2017
Director, since 26-06-2017
- 100 sharesdeed of 28-06-2017
Recent changes
Registered in the Peppol Directory
Reachable for e-invoices through 0208:0677563014
Company renamed from Cabimed 74 Dr to Cabimed 74
Change of role: , from manager to director · “En assurant la gestion d'un centre médical ou d'un cabinet médical,en ce compris l'acquisition,la location et…” (deed in French) · Director discharge: (manager) · General meeting of 15-11-2022 · Gazette deed
Publication in the Belgian Official Gazette
Gazette deed
Incorporation
Founding capital of €18,600, 100 shares, €12,400 paid up · Founder: · Appointment: (manager) · published on 28-06-2017 · Gazette deed
Comparable companies
same main activity, similar in size and age| Company | ||||
|---|---|---|---|---|
| Cabimed 74 Nivelles | €214,647 | €107,372 | 15.6% | - |
| DOKTER KAAT KNAPEN Temse | €221,280 | €104,869 | 28.2% | - |
| DOCTEUR SANDRINE BRUTSAERT Schaerbeek | €226,042 | €101,263 | 17.3% | - |
| Dr. Makay Nicolas Mechelen | €225,903 | €113,938 | 35.9% | - |
| Docteur Mouton Charlotte, Médecine Générale Gembloux | €207,554 | €101,302 | 26.4% | - |
| CABINET DOCTEUR PARMENTIER Beloeil | €208,761 | €99,367 | 12.6% | - |
| Dr. Yves Vloemans Kasterlee | €185,949 | €109,805 | 46.8% | - |
These companies have the same main activity as Cabimed 74: general medical practice (NACE 86210). They are comparable in size and age: total assets between €186,000 and €226,000, founded between 2016 and 2018.
Official details
Source: KBO- Status
- Active since 26-06-2017Normal situation
- Activity
- General medical practiceNACE 86210
- Establishment unit
- 2.265.637.1161400 Nivelles, since 26-06-2017
- Financial year end
- 31 December
- Peppol
- Reachable since 11-06-2025
Annual accounts 2025
- €214,647▲ 4.3%
- Filing
- Filed on 26-06-2026, 35 days before the end of the filing period
Insights on Cabimed 74
Cabimed 74 files the micro format. That format states no turnover. The gross margin rose from €36,394 in 2017 to €107,372 in 2025.
The balance sheet grew most in 2023 through fixed assets.
Sources: KBO register, filings at the National Bank, Belgian Official Gazette. Click a figure with a dotted line for the item and the filing.
Key facts about Cabimed 74
- What is the company number of Cabimed 74?
- The company number of Cabimed 74 is 0677.563.014. The VAT number is the same number with BE in front: BE 0677.563.014.
- Where is Cabimed 74 based?
- The registered office is at Mont Saint-Roch 32, 1400 Nivelles.Company details
- What does Cabimed 74 do?
- According to the KBO register, the main activity is general medical practice (NACE 86210).
- What is the legal form of Cabimed 74?
- Cabimed 74 is a private limited company (BV).
- When was Cabimed 74 founded?
- Cabimed 74 was founded on 26-06-2017.
- Is Cabimed 74 still active?
- Yes, Cabimed 74 is an active enterprise in the KBO register.
- What is the turnover of Cabimed 74?
- The turnover of Cabimed 74 was €224,544 in financial year 2025, according to the filed annual accounts.Financials
- Is Cabimed 74 profitable?
- In financial year 2025, Cabimed 74 made a profit of €57,246.
- Where can I find the annual accounts of Cabimed 74?
- Cabimed 74 filed 9 annual accounts with the National Bank of Belgium, the latest for financial year 2025.
- When are the next annual accounts of Cabimed 74 due?
- Cabimed 74 must file the annual accounts for financial year 2026 by 31-07-2027.Timeline
Next steps
Work out how much credit to give this customer and on what payment terms.Credit check Check what to know before you do business with this company.Supplier due diligence Check whether you can accept this company as a client under the anti-money-laundering law.AML client file Check which of your other customers you can e-invoice via Peppol.Peppol check Compare this company with its sector.Sector benchmark See what changed in the latest annual accounts.What changed
See how customers, suppliers and banks see your own company and what to improve first.